• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Diagnostics & Pathology in India Product Image

Diagnostics & Pathology in India

  • ID: 992726
  • April 2009
  • Region: India
  • 67 Pages
  • Cygnus Research

FEATURED COMPANIES

  • Anand Labs
  • Dr Lal Pathlabs
  • Religare SRL Diagnostics
  • Thyrocare
  • MORE

According to Cygnus estimates, the Indian diagnostic and pathological labs test services market was valued at Rs66.87 billion in FY2008. Indian diagnostics and pathological labs, based on the working level, are classified into high-end labs, accounting for 38% of the market share, manual labs (28%) and second-level regional labs (34%). By therapeutic segment, the major share is held by biochemistry (38%), followed by immunology (23%), haematology (15.8%), critical care, urine routine, others, microbiology and coagulation. Seventy seven per cent of the market is contributed by biochemistry and clinical pathology, which includes immunology and haematology. According to the estimates, the Indian diagnostics and labs test services, in view of its growth potential, is expected to reach Rs159.89 billion by FY2013, reflecting a CAGR of 18.9% during FY09-FY13. Applications of molecular diagnostic testing will revolutionise clinical practices with major implications, opportunities and challenges for the labs.

In the backdrop of this encouraging scenario, Cygnus has come up with an industry analysis of diagnostics and pathology test laboratories. The report comprises eight chapters. It READ MORE >

FEATURED COMPANIES

  • Anand Labs
  • Dr Lal Pathlabs
  • Religare SRL Diagnostics
  • Thyrocare
  • MORE

EXECUTIVE SUMMARY HIGHLIGHTS

Industry & Market Overview
- Global medical and diagnostics laboratory
- Indian healthcare industry
-- Market Size and Growth
-- Healthcare infrastructure
-- Overview of diagnostics & pathology laboratory industry
-- Existing Business Models

Accreditations & Quality Control
- Introduction
- National Accreditation Board for Testing & Calibration Laboratories
- College for American Pathologist
-- Benefits of CAP Accreditation
- Effect of the accreditation process among the clinical labs
-- Quality manual
-- Quality System Procedure
-- Standard Test Operating Procedure (SOP)
-- Records
-- Quality control (Interlab/external)
-- Internal audit
-- Overall cost/expenses for Audit

MAJOR PLAYERS
- Introduction
- Metropolis Health Services (India) Ltd.
-- Company Background
-- Contact Address
-- Management Team
-- Infrastructure & Accreditations
-- Business Strategy & Competitive Advantages
-- Outlook
- Religare SRL Diagnostics
-- Company Background
-- Contact Address
-- Management Team
-- Infrastructure & Accreditations
-- Business Strategy & Competitive Advantages
-- Outlook
- Piramal Diagnostics Services Pvt. Ltd. (PDSL)
-- Company Background
-- Contact Address
-- Management Team
-- Infrastructure & Accreditations
-- Business Strategy & Competitive Advantages
-- Outlook
- Dr Lal Pathlabs
-- Company Background
-- Contact Address
-- Management Team
-- Infrastructure & Accreditations
-- Business Strategy & Competitive Advantages
-- Outlook
- Thyrocare
-- Company Background
-- Contact Address
-- Management Team
-- Infrastructure & Accreditations
-- Business Strategy & Competitive Advantages
-- Outlook
- Anand Labs
-- Company Background
-- Contact Address
-- Management Team
-- Infrastructure & ccreditations
-- Business Strategy & Competitive Advantages
-- Outlook
- Quest Diagnostics India Pvt. Ltd.
-- Company Background
-- Contact Address
-- Management Team
-- Infrastructure & Accreditations
-- Business Strategy & Competitive Advantages
-- Outlook

GROWTH DRIVERS
- Introduction
- Healthcare Institutes
-- Foreign hospitals outsourcing diagnostics tests
-- Polyclinics
-- Pharmacies
-- Medical KPO
- Healthcare Services
-- CRO
-- Molecular diagnostics
-- Pharmacogenomics
- Theranostics, driving diagnostic test in drug development
- Logistics and Infrastructure
- IT Infrastructure and Network
- Insurance

CRITICAL SUCCESS FACTORS
- Automation and standardisation
- Success of tests
- Processing blood samples
- Laboratory accreditation

ISSUES AND CHALLENGES
- Regulatory issues
- Reimbursement pressures
- Analytical and quality issues
- Accreditation procurement

Recent Trends
- Diagnostics Majors Mull over Outsourced Path Lab Management
- Consolidation in Diagnostics Services
- Diagnostics and Pathology Market Set to Flourish

Future Outlook

ANNEXURE I
- Bibliography

ANNEXURE II
- Glossary

List of Tables

- Molecular Diagnostics Technologies
- Public healthcare physical infrastructure

List of Figures
- Indian Healthcare Market Size (FY03-FY08)
- Healthcare Expenditure (2007)
- Medical Devices & Diagnostics Market (2008)
- Indian Diagnostics & Pathology Test Market (2005-2008)
- Structure of Diagnostics & Pathology Labs Industry
- Indian Diagnostics and Pathology Market (2008)
- Indian Diagnostics and Pathological Test Market by Therapeutic Segment – 2008
- Referral Lab business model
- Indian Diagnostic and Path Labs Market Forecast (2008-13)

FEATURED COMPANIES

  • Anand Labs
  • Dr Lal Pathlabs
  • Religare SRL Diagnostics
  • Thyrocare
  • MORE

The Indian healthcare industry, comprising the pharmaceuticals industry, medical devices, diagnostic and pathological lab services, stood at Rs2,917.85 billion in FY2008, a growth of 15.7% compared to Rs2,521.47 billion in FY2007. The public expenditure has grown to 18% and private expenditure accounts for 82% of the total healthcare expenditure in FY2007. The medical devices and diagnostics market was estimated to be Rs128.35 billion in FY2008 of which medical devices constituted 36.67%, followed by medical equipments holding 11.23% and diagnostics and pathological test holding 52.1% of the share. The Indian diagnostic and pathological labs test services market is valued at Rs66.87 billion in FY2008, according to Cygnus estimates.

The diagnostics and pathology laboratory industry comprises more than 100,000 laboratories out of which very few are accredited to provide formal recognition of testing and calibration services. The major pathological testing laboratories service for 3,000 samples per day. The regional laboratories and hospital facilities service on average 1,000 samples per day. Laboratories in the smaller town and rural areas service 50-100 samples per day. There are two types of diagnostic and pathology labs—corporate labs and hospital labs. The corporate labs have franchises, hub labs and tie up labs, whereas the hospital run labs are entirely managed by the hospitals.

Indian diagnostics and pathological labs, based on the working level, are classified into high-end labs, accounting for 38% of the market share, manual labs (28%) and second-level regional labs (34%). By therapeutic segment, the major share is held by biochemistry (38%), followed by immunology (23%), haematology (15.8%), critical care, urine routine, others, microbiology and coagulation. 77% of the market is contributed by biochemistry and clinical pathology, which includes immunology and haematology.

The major players in diagnostics and pathological test labs market are Metropolis, Religare SRL Diagnostics, Dr Lal’s Pathology, Piramal Diagnostics (formerly Wellspring), Thyrocare and Anand Labs. Metropolis plans to continue with its consolidation practices and add about five more labs in 2009. Religare SRL Diagnostics has a fine network comprising South East Asia's largest central clinical reference laboratory, 35 satellite laboratories and over 800 collection centres. Dr Lal Pathlabs intends to increase its presence in Southern and Western India and achieve Rs2 billion turnover in 2009-10. Thyrocare has tied up with 14 to 15 pharmaceutical companies, and it has more than 600 dedicated collection centres across India.

The major demand for therapeutic devices and techniques comes from hospitals, polyclinics, pharmacies and medical KPO. The development of Clinical Research Organisations (CRO) and molecular diagnostics in the future will increase the opportunity for viral diagnostics, immune system diagnostics, bacterial, parasitic and fungal identification and cancer diagnosis. Insurance companies have tied up with labs to conduct their pre-policy check ups. This collaboration has changed the functioning of the hospitals and diagnostics and pathological labs in the country.

It is of paramount importance for the diagnostics and pathology laboratory industry to adopt IT applications in managing laboratory database if they want to get the leverage of potential lab tests outsourcing. Accuracy of test results through properly laid test procedures and qualified/trained manpower is another critical success factor. Accreditation of course is another pillar of success in this industry.

The government needs to bring in licensing and logistics issues should be settled before India becomes a hub for outsourcing laboratory tests. Challenges also exist in the development and application of accreditation standards for diagnostic labs, to ensure recognition and acceptance of data by states, regulatory agencies and partners. This issue is being dealt by National Plant Diagnostic Network (NPDN).

According to Cygnus estimates, the Indian diagnostics and labs test services, in view of its growth potential, is expected to reach Rs159.89 billion by FY2013, reflecting a CAGR of 18.9% during FY09-FY13. Applications of molecular diagnostic testing will revolutionise clinical practices with major implications, opportunities and challenges for the labs.

- Metropolis Health Services (India) Ltd.
- Religare SRL Diagnostics
- Piramal Diagnostics Services Pvt. Ltd. (PDSL)
- Dr Lal Pathlabs
- Thyrocare
- Anand Labs
- Quest Diagnostics India Pvt. Ltd.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos